analogue

(redirected from purine analogue)
Also found in: Dictionary, Thesaurus, Medical.

analogue

(sometimes US), analog
1. 
a. a physical object or quantity, such as a pointer on a dial or a voltage, used to measure or represent another quantity
b. (as modifier): analogue watch
2. Biology an analogous part or organ
3. Chem
a. an organic chemical compound related to another by substitution of hydrogen atoms with alkyl groups
b. an organic compound that is similar in structure to another organic compound

analogue

(electronics)
(US: "analog") A description of a continuously variable signal or a circuit or device designed to handle such signals. The opposite is "discrete" or "digital".

Analogue circuits are much harder to design and analyse than digital ones because the designer must take into account effects such as the gain, linearity and power handling of components, the resistance, capacitance and inductance of PCB tracks, wires and connectors, interference between signals, power supply stability and more. A digital circuit design, especially for high switching speeds, must also take these factors into account if it is to work reliably, but they are usually less critical because most digital components will function correctly within a range of parameters whereas such variations will corrupt the outputs of an analogue circuit.

See also analogue computer.

analogue

The British and European spelling of analog.
References in periodicals archive ?
[25] also described a CLL patient who received a purine analogue, fludarabine, and on relapse rituximab and subsequently developed a nasopharyngeal mass that was consistent with PBL and cervical adenopathy that was consistent with classical Hodgkin lymphoma, both EBV positive.
Multivariate analysis showed that uncontrolled disease at the time of alloHSCT and in vivo T-cell depletion with alemtuzumab, but no del 17p, previous purine analogue refractoriness, and donor source (human leukocyte antigen-identical siblings or unrelated donors) had an adverse impact on EFS and OS, indicating that alloHSCT can result in long-term MRD-negative survival in up to 50% of patients, independent of the underlying genomic risk profile.
In physically fit patients FCR (Fludarabine, Cyclophosphamide, Rituximab) is the standard first-line therapy.7 Combinations based on other purine analogues such as cladribine8 or pentostatin9 have shown similar activity, but it is uncertain whether they can replace fludarabine in FCR regimen.